No Data
tianjin chase sun pharmaceutical (300026.SZ): the company's class I innovative lung cancer drug PTS does not involve genetic testing before clinical application.
Gelonghui November 6th | Tianjin Chase Sun Pharmaceutical (300026.SZ) stated on the investor interaction platform that the company's Class I innovative lung cancer drug PTS does not involve genetic testing before clinical application.
tianjin chase sun pharmaceutical (300026.SZ): No products are involved in this year's medical insurance negotiations.
Gelonghui November 1st, tianjin chase sun pharmaceutical (300026.SZ) stated on the investor interaction platform that the company currently has no products involved in this year's medical insurance negotiations.
Hongri Pharmaceutical: Report for the third quarter of 2024
Express News | tianjin chase sun pharmaceutical: net income in the first three quarters was 0.168 billion yuan, a year-on-year decrease of 66.94%.
Tianjin Chase Sun Pharmaceutical (300026.SZ): The net income for the third quarter was 20.1245 million yuan, a year-on-year decrease of 87.68%.
On October 24th, Gelonhui reported that Tianjin Chase Sun Pharmaceutical (300026.SZ) achieved revenue of 1.445 billion yuan in the third quarter of 2024, a 3.61% year-on-year decrease; net income attributable to the shareholders of the listed company was 20.1245 million yuan, a decrease of 87.68% year-on-year; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 20.786 million yuan, a decrease of 82.65% year-on-year; basic earnings per share was 0.01 yuan.
Express News | Tianjin Modern Traditional Chinese Medicine New Quality Productivity Technology Innovation Project Launched
No Data
No Data